...
首页> 外文期刊>Biomarkers >Improving clinical prediction rules in acute kidney injury with the use of biomarkers of cell cycle arrest: a pilot study
【24h】

Improving clinical prediction rules in acute kidney injury with the use of biomarkers of cell cycle arrest: a pilot study

机译:利用细胞周期阻滞生物标志物改善急性肾损伤的临床预测规则:一项初步研究

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Early recognition of patients developing acute kidney injury (AKI) is of considerable interest, we report the first use of a combination of a clinical prediction rule with a biomarker in emergent adult medical patients to improve AKI recognition. Methods: Single-centre prospective pilot study of medical admissions without AKI identified as high risk by a clinical prediction rule. Urine samples were obtained and tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) - biomarkers associated with cell cycle arrest, were measured. Outcome: Creatinine-based KDIGO hospital-acquired AKI (HA-AKI). Results: Of 69 patients recruited, HA-AKI developed in 13% (n = 9), in whom biomarker values were higher (median 0.43 (interquartile range (IQR) 0.21-1.25) vs. 0.07 (0.03-0.16) in cases without (p = 0.008). Peak rise in creatinine was higher in biomarker positive cases (median 30 mu mol/L (7-72) vs. 1 mu mol/L (0-16), p = 0.002). AUROC was 0.78 (95% CI 0.57-0.98). At the suggested cut-off (0.3) sensitivity for predicting AKI was 78% (95% CI 40-97%), specificity 89% (78-95%), positive predictive value 50% (31-69%) and negative predictive value 96% (89-99%). Discussion: Addition of a urinary biomarker allows exclusion of a significant number of patients identified to be at higher risk of AKI by a clinical prediction rule.
机译:简介:早期识别发展为急性肾损伤(AKI)的患者引起了广泛的兴趣,我们报道了在新兴成人医学患者中首次将临床预测规则与生物标志物结合使用以提高AKI识别率。方法:单中心前瞻性研究对无AKI的入院患者进行临床预测规则确定为高风险。获得尿液样品,并测量金属蛋白酶2(TIMP-2)和胰岛素样生长因子结合蛋白7(IGFBP7)的组织抑制剂-与细胞周期停滞有关的生物标志物。结果:基于肌酐的KDIGO医院获得的AKI(HA-AKI)。结果:在征募的69例患者中,HA-AKI发生率为13%(n = 9),其中生物标志物值较高(中位数为0.43(四分位间距(IQR)0.21-1.25),而未标记者为0.07(0.03-0.16)) (p = 0.008)。在生物标志物阳性病例中,肌酐的峰值升高更高(中位30μmol / L(7-72)比1 mu mol / L(0-16),p = 0.002)。AUROC为0.78( 95%CI 0.57-0.98)。在建议的临界(0.3)预测AKI的敏感性为78%(95%CI 40-97%),特异性89%(78-95%),阳性预测值50%( 31-69%)和阴性预测值96%(89-99%)讨论:添加尿液生物标志物可以排除根据临床预测规则确定为AKI风险较高的大量患者。

著录项

  • 来源
    《Biomarkers》 |2019年第8期|23-28|共6页
  • 作者

  • 作者单位

    Univ Southampton Acad Unit Primary Care & Populat Sci Southampton Gen Hosp Fac Med Southampton Hants England|Worthing Dist Hosp Western Sussex Hosp NHS Fdn Trust Anaesthet Dept Worthing England;

    Worthing Dist Hosp Western Sussex Hosp NHS Fdn Trust Anaesthet Dept Worthing England;

    Univ Southampton Acad Unit Primary Care & Populat Sci Southampton Gen Hosp Fac Med Southampton Hants England;

    Univ Nottingham Div Med Sci & Grad Entry Med Ctr Kidney Res & Innovat Nottingham England|Royal Derby Hosp Dept Renal Med Derby England;

    Royal Surrey Cty Hosp NHS Fdn Trust Intens Care Dept Guildford Surrey England|Univ Surrey Dept Clin & Expt Med Fac Hlth Sci Guildford Surrey England;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Acute kidney injury (AKI); tissue inhibitor of metalloproteinases-2 (TIMP-2); insulin-like growth factor binding protein 7 (IGFBP7);

    机译:急性肾损伤(AKI);金属蛋白酶2的组织抑制剂(TIMP-2);胰岛素样生长因子结合蛋白7(IGFBP7);

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号